Also, GM-CSF administration in a phase Ib/II clinical trial on renal cell carcinoma has been associated with acute multifocal cerebral venous thrombosis and subdural and subarachnoid hemorrhage [63]. Here, CSF2 is linked to hereditary clear cell renal cell carcinoma.